XML 28 R19.htm IDEA: XBRL DOCUMENT
v3.26.1

Accrued Expenses and Other Current Liabilities | 6 Months Ended
--- | ---
Jun. 30, 2026
Payables and Accruals [Abstract] |
Accrued Expenses and Other Current Liabilities | 11. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands):
|  | June 30, 2026 |  |  | December 31, 2025 |
Product revenue allowances |  | $ | 11,115 |  |  | $ | 9,810 |
Accrued clinical study and trial costs |  |  | 20,878 |  |  |  | 18,977 |
Accrued selling, general, and administrative costs |  |  | 6,483 |  |  |  | 6,316 |
Accrued compensation and related costs |  |  | 11,384 |  |  |  | 24,352 |
Accrued milestone costs |  |  | — |  |  |  | 10,000 |
Accrued royalty payable |  |  | 8,183 |  |  |  | 7,372 |
Accrued interest - royalty interest financing |  |  | 34,149 |  |  |  | 25,516 |
Accrued interest - convertible note |  |  | 555 |  |  |  | — |
Other |  |  | 1,550 |  |  |  | 721 |
Total accrued expenses and other current liabilities |  | $ | 94,297 |  |  | $ | 103,064 |

X
- Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details
Name: | us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration